Treatment with drugs known to affect mainly the urinary function 14 days prior to starting completion of the baseline diary for Visit 2

Participation in a bladder-training program

Low compliance bladder (Compliance \<20 mL/cm H2O)

DSD, Detrusor hyporeflexia / areflexia and bradykinesia / tremor of the external urethral sphincter

Indwelling catheter or intermittent self-catheterization

Patience with post-void residual (PVR) urinary volume \> 200 mL at baseline

Urinary retention or clinically significant bladder outlet obstruction as detected by the investigator

Clinically predominant and bothersome stress urinary incontinence

Neurological diseases other than multiple sclerosis affecting urinary bladder function

Any urogenital surgery within 12 month prior to Visit 1

Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity